MCID: HPT022
MIFTS: 54

Hepatoblastoma

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Hepatoblastoma

MalaCards integrated aliases for Hepatoblastoma:

Name: Hepatoblastoma 12 50 29 52 42 14 69
Hbl 12

Classifications:



External Ids:

Disease Ontology 12 DOID:687
ICD10 33 C22.2
MeSH 42 D018197
NCIt 47 C3728
SNOMED-CT 64 109843000 45024009
UMLS 69 C0206624

Summaries for Hepatoblastoma

NIH Rare Diseases : 50 hepatoblastoma is a rare malignant (cancerous) tumor of the liver that usually occurs in the first 3 years of life. in early stages of the condition, there may be no concerning signs or symptoms. as the tumor gets larger, affected children may experience a painful, abdominal lump; swelling of the abdomen; unexplained weight loss; loss of appetite; and/or nausea and vomiting. the exact underlying cause of hepatoblastoma is poorly understood. risk factors for the tumor include prematurity with a very low birth weight, early exposure to hepatitis b infection, biliary atresia, and several different genetic conditions (i.e. beckwith-wiedemann syndrome, familial adenomatous polyposis, aicardi syndrome, glycogen storage disease, and simpson-golabi-behmel syndrome). treatment varies based on the severity of the condition but may include a combination of surgery, watchful waiting, chemotherapy, and/or radiation therapy. last updated: 1/20/2016

MalaCards based summary : Hepatoblastoma, also known as hbl, is related to hepatocellular carcinoma and mixed hepatoblastoma, and has symptoms including icterus An important gene associated with Hepatoblastoma is APC (APC, WNT Signaling Pathway Regulator), and among its related pathways/superpathways are Development HGF signaling pathway and PI3K-Akt signaling pathway. The drugs Lenograstim and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include liver, fetal liver and testes, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cellular

Wikipedia : 72 Hepatoblastoma is an uncommon malignant liver cancer occurring in infants and children and composed of... more...

Related Diseases for Hepatoblastoma

Diseases related to Hepatoblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 146)
id Related Disease Score Top Affiliating Genes
1 hepatocellular carcinoma 28.7 ABCB1 AFP APC BCL2L1 BIRC5 CASP3
2 mixed hepatoblastoma 12.0
3 macrotrabecular hepatoblastoma 11.8
4 beckwith-wiedemann syndrome 11.2
5 hypobetalipoproteinemia, familial, 2 11.1
6 high-grade dysplasia in patients with barrett esophagus 10.9 H19 IGF2
7 familial rhabdoid tumor 10.9 H19 IGF2
8 hallermann-streiff syndrome 10.9 H19 IGF2
9 aapoaii amyloidosis 10.9 H19 IGF2
10 chylomicron retention disease 10.8
11 anencephaly 10.8 APC CTNNB1
12 neonatal urinary tract infectious disease 10.6 BCL2L1 CASP3
13 mediastinal mesenchymal tumor 10.6 AFP GPC3
14 secondary non-traumatic avascular necrosis 10.6 CDKN1C IGF2
15 colon signet ring adenocarcinoma 10.5 AFP APC CTNNB1 IGF2
16 eccrine acrospiroma 10.5 AFP KRT7
17 visual cortex disease 10.5 AFP GPC3
18 fetal parvovirus syndrome 10.5 APOA1 H19 IGF2
19 biliary tract neoplasm 10.4 IGF2 KRT7
20 periosteal osteogenic sarcoma 10.4 CTNNB1 KRT7
21 childhood-onset schizophrenia 10.4 CTNNB1 MET
22 hemoglobin zurich 10.4 CDKN1C H19 IGF2
23 sleep disorder 10.4 AFP APOA1 GPC3
24 breast abscess 10.4 CDKN1C H19 IGF2
25 gastrointestinal neuroendocrine tumor 10.3 CTNNB1 KRT7 PLAG1
26 clear cell squamous cell skin carcinoma 10.3 AFP KRT7
27 cerebellar vermis medulloblastoma 10.3 AFP GPC3 KRT7
28 focal epithelial hyperplasia 10.3 AFP GPC3 KRT7
29 vestibular gland benign neoplasm 10.3 CTNNB1 KRT7 PLAG1
30 pulmonary coin lesion 10.3 AFP GPC3 KRT7
31 monoclonal paraproteinemia 10.3 ABCB1 CASP3 CTNNB1
32 male reproductive organ benign neoplasm 10.3 CTNNB1 KRT7 PLAG1
33 nail disorder, nonsyndromic congenital, 1 10.2 ABCB1 BIRC5 CASP3 CTNNB1
34 rare endometriosis 10.2 BIRC5 CTNNB1 KRT7
35 hepatitis 10.2
36 platelet glycoprotein iv deficiency 10.2 HGF MET
37 aromatic l-amino acid decarboxylase deficiency 10.2 CDKN1C H19 IGF2 PLAG1
38 apocrine adenocarcinoma 10.2 AFP CTNNB1 GPC3 KRT7
39 brown-vialetto-van laere syndrome 10.1 AFP CASP3 CTNNB1 KRT7
40 osteofibrous dysplasia 10.1 HGF MET
41 solitary osseous plasmacytoma 10.1 AFP CASP3 CTNNB1
42 epileptic encephalopathy, early infantile, 3 10.1 ABCB1 SLC22A18
43 childhood optic nerve glioma 10.1 APC CTNNB1 KRT7 PLAG1
44 familial adenomatous polyposis 10.0
45 diabetes mellitus, insulin-dependent, 20 10.0 AFP APC CTNNB1 GPC3 HNF1A
46 thoracic outlet syndrome 10.0 AFP CDKN1C KRT7
47 pulmonary subvalvular stenosis 10.0 BIRC5 CASP3 MET
48 neuroblastoma 9.9
49 hepatitis b 9.9
50 sarcomatoid squamous cell skin carcinoma 9.9 HGF MET

Graphical network of the top 20 diseases related to Hepatoblastoma:



Diseases related to Hepatoblastoma

Symptoms & Phenotypes for Hepatoblastoma

UMLS symptoms related to Hepatoblastoma:


icterus

GenomeRNAi Phenotypes related to Hepatoblastoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.96 CTNNB1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.96 CTNNB1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.96 AFP
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.96 IGF2
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.96 AFP
6 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.96 IGF2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.96 APC
8 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.96 KRT7
9 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.96 IGF2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.96 IGF2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.96 APC CTNNB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-192 9.96 KRT7 AFP APC
13 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.96 CTNNB1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.96 APC
15 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.96 AFP APC
16 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.96 CTNNB1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.96 APC CTNNB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.96 IGF2 AFP
19 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.96 IGF2 CTNNB1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.96 CTNNB1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.96 IGF2 KRT7 APC CTNNB1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.96 CTNNB1 IGF2

MGI Mouse Phenotypes related to Hepatoblastoma:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.34 HGF HNF1A IGF2 KRT7 MET PPARA
2 cardiovascular system MP:0005385 10.28 HGF IGF2 MET PPARA ABCB1 APC
3 homeostasis/metabolism MP:0005376 10.28 ABCB1 AFP APC APOA1 BCL2L1 BIRC5
4 endocrine/exocrine gland MP:0005379 10.27 ABCB1 AFP APC APOA1 BCL2L1 BIRC5
5 growth/size/body region MP:0005378 10.25 ABCB1 APC BCL2L1 CASP3 CDO1 CTNNB1
6 digestive/alimentary MP:0005381 10.1 APC CASP3 CTNNB1 GPC3 HNF1A IGF2
7 mortality/aging MP:0010768 10.1 MET PPARA ABCB1 AFP APC BCL2L1
8 embryo MP:0005380 10.08 APC BIRC5 CTNNB1 GPC3 HGF IGF2
9 craniofacial MP:0005382 10.05 APC CASP3 CDO1 CTNNB1 GPC3 IGF2
10 integument MP:0010771 10.02 APC APOA1 BCL2L1 CASP3 CTNNB1 GPC3
11 liver/biliary system MP:0005370 10.02 ABCB1 AFP APC APOA1 CTNNB1 HGF
12 no phenotypic analysis MP:0003012 9.76 ABCB1 APC CASP3 CTNNB1 HGF HNF1A
13 renal/urinary system MP:0005367 9.56 APC CASP3 CTNNB1 GPC3 HNF1A IGF2
14 reproductive system MP:0005389 9.36 BCL2L1 CASP3 CDO1 CTNNB1 GPC3 HNF1A

Drugs & Therapeutics for Hepatoblastoma

Drugs for Hepatoblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved Phase 4,Phase 1 135968-09-1
2
Nicotine Approved Phase 4 54-11-5 942 89594
3 Adjuvants, Immunologic Phase 4,Phase 1
4
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
5
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
6
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
7
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
8
Etoposide Approved Phase 3,Phase 1,Phase 2 33419-42-0 36462
9
Amifostine Approved, Investigational Phase 3,Phase 1 20537-88-6 2141
10
Fluorouracil Approved Phase 3 51-21-8 3385
11
Vincristine Approved, Investigational Phase 3,Phase 1 2068-78-2, 57-22-7 5978
12
Oxaliplatin Approved, Investigational Phase 3,Phase 2 61825-94-3 5310940 9887054 43805 6857599
13
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
14
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
15
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
16
Gemcitabine Approved Phase 3 95058-81-4 60750
17
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
18
Cyproheptadine Approved Phase 3 129-03-3 2913
19
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
20
Doxil Approved June 1999 Phase 3,Phase 2 31703
21
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
22 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
23 Antidotes Phase 3
24 Anti-Infective Agents Phase 3,Phase 2,Phase 1
25 Antioxidants Phase 3
26 Antitubercular Agents Phase 3
27 Chelating Agents Phase 3
28 Liver Extracts Phase 3,Phase 2,Phase 1
29 Protective Agents Phase 3,Phase 1
30 sodium thiosulfate Phase 3
31 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
32 Immunosuppressive Agents Phase 3,Phase 1,Phase 2
33 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
34 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
35 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
36 Etoposide phosphate Phase 3,Phase 1,Phase 2
37 Antimetabolites Phase 3,Phase 1
38 Antimetabolites, Antineoplastic Phase 3
39 Antimitotic Agents Phase 3,Phase 1
40 Radiation-Protective Agents Phase 3,Phase 1
41 Antifungal Agents Phase 3,Phase 2,Phase 1
42 Hematinics Phase 3
43 Antiviral Agents Phase 3
44 Protein Kinase Inhibitors Phase 3
45 Complement C3a Phase 3
46 Anti-Allergic Agents Phase 3
47 Antipruritics Phase 3
48 Dermatologic Agents Phase 3
49 Gastrointestinal Agents Phase 3
50 Histamine Antagonists Phase 3

Interventional clinical trials:

(show all 44)

id Name Status NCT ID Phase Drugs
1 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Not yet recruiting NCT02933333 Phase 4
2 Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, Stage II, or Stage III Childhood Liver Cancer Unknown status NCT00652132 Phase 3 cisplatin;sodium thiosulfate
3 Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer Completed NCT00003994 Phase 3 cisplatin;vincristine sulfate;fluorouracil;amifostine trihydrate;carboplatin
4 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
5 Chemotherapy in Treating Children With Liver Cancer Completed NCT00003912 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride
6 Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Recruiting NCT00980460 Phase 3 Cisplatin;Doxorubicin Hydrochloride;Fluorouracil;Irinotecan Hydrochloride;Temsirolimus;Vincristine Sulfate
7 Paediatric Hepatic International Tumour Trial Recruiting NCT03017326 Phase 3 Cisplatin;Doxorubicin;Carboplatin;5Fluorouracil;Vincristine;Etoposide;Irinotecan;Gemcitabine;Oxaliplatin;Sorafenib
8 Study to Assess Safety and Efficacy of ELAD in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure Terminated NCT01829347 Phase 3
9 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
10 Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma Unknown status NCT00287976 Phase 2 irinotecan hydrochloride
11 Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma Unknown status NCT00077389 Phase 2 carboplatin;cisplatin;doxorubicin hydrochloride
12 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
13 A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB Completed NCT01125800 Phase 1, Phase 2 LDE225
14 Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Completed NCT01154816 Phase 2 Alisertib
15 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
16 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
17 Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors Completed NCT00024258 Phase 2 arsenic trioxide
18 Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Recruiting NCT01956669 Phase 2 Pazopanib GW786034
19 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib S-malate
20 Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations Recruiting NCT03220035 Phase 2 Vemurafenib
21 Pediatric MATCH: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes Recruiting NCT03233204 Phase 2 Olaparib
22 Pediatric MATCH: Trk Inhibitor LOXO-101 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions Recruiting NCT03213704 Phase 2 Larotrectinib
23 Pediatric MATCH: PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations Recruiting NCT03213678 Phase 2 PI3K/mTOR Inhibitor LY3023414
24 Pediatric MATCH: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations Recruiting NCT03213665 Phase 2 Tazemetostat
25 Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Vemurafenib
26 A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors Recruiting NCT01804634 Phase 2 Cyclophosphamide;Fludarabine;Melphalan;Sirolimus
27 Pediatric MATCH: Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations Not yet recruiting NCT03210714 Phase 2 Erdafitinib
28 Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors Withdrawn NCT02011126 Phase 2 imetelstat sodium
29 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors Unknown status NCT00007813 Phase 1 carboplatin;cyclophosphamide;etoposide
30 Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors Recruiting NCT02390843 Phase 1 Simvastatin;Cyclophosphamide;Topotecan;Myeloid growth factor
31 Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Active, not recruiting NCT01331135 Phase 1 sirolimus
32 A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy Active, not recruiting NCT02085148 Phase 1 Regorafenib (BAY73-4506);Vincristine (Cellcristin®);Irinotecan (Irinotecan Cell pharm®)
33 Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors Terminated NCT00003926 Phase 1 amifostine trihydrate;busulfan;filgrastim;melphalan;thiotepa
34 MT2004-30: Tomotherapy for Solid Tumors Terminated NCT00623077 Phase 1 busulfan;etoposide;ifosfamide;melphalan;thiotepa;Mesna
35 Cancer and Hearing Loss Related in Children Unknown status NCT02425397
36 Biomarkers in Tissue Samples From Young Patients With Liver Cancer Completed NCT01336881
37 Gene Mutation in Samples From Young Patients With Pleuropulmonary Blastoma Syndrome at Risk for Developing Cancer Completed NCT01353300
38 Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer Completed NCT00002485
39 Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience Recruiting NCT02557750
40 Understanding Communication in Healthcare to Achieve Trust (U-CHAT) Recruiting NCT02846038
41 Auto Transplant for High Risk or Relapsed Solid or CNS Tumors Recruiting NCT01505569 Ifosfamide;Etoposide;Mesna;Busulfan;Melphalan;Thiotepa;Carboplatin;Paclitaxel
42 Collecting and Storing Tissue From Young Patients With Cancer Recruiting NCT00898755
43 Hepatoblastoma Biology Study and Tissue Bank Withdrawn NCT00228683
44 Early Enteral Tube Feedings in Children Receiving Chemo for AML/MDS & High Risk Solid Tumors Withdrawn NCT00624962

Search NIH Clinical Center for Hepatoblastoma

Cochrane evidence based reviews: hepatoblastoma

Genetic Tests for Hepatoblastoma

Genetic tests related to Hepatoblastoma:

id Genetic test Affiliating Genes
1 Hepatoblastoma 29

Anatomical Context for Hepatoblastoma

MalaCards organs/tissues related to Hepatoblastoma:

39
Liver, Fetal Liver, Testes, Lung, Kidney, Brain, Heart

Publications for Hepatoblastoma

Articles related to Hepatoblastoma:

(show top 50) (show all 820)
id Title Authors Year
1
Serum alpha-fetoprotein screening for hepatoblastoma in Beckwith-Wiedemann syndrome. ( 28211991 )
2017
2
A common global risk stratification system for hepatoblastoma. ( 27884678 )
2017
3
Mutant CTNNB1 and histological heterogeneity define metabolic subtypes of hepatoblastoma. ( 28923827 )
2017
4
Fine needle aspiration in the diagnosis and classification of hepatoblastoma: Analysis of 21 New Cases. ( 27933740 )
2017
5
Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Children's Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Children's Oncology Group. ( 28892430 )
2017
6
Hepatoblastoma in an 11-year-old: Case report and a review of the literature. ( 28079820 )
2017
7
Split liver transplantation for retroperitoneal immature teratoma masquerading as hepatoblastoma. ( 28714114 )
2017
8
Extreme hepatic resections for the treatment of advanced hepatoblastoma: Are planned close margins an acceptable approach? ( 28921939 )
2017
9
Molecular classification of hepatoblastoma and prognostic value of the HB 16-gene signature. ( 28510309 )
2017
10
The role of pulmonary metastasectomy for hepatoblastoma in children with metastasis at diagnosis: Results from the JPLT-2 study. ( 28927977 )
2017
11
Hepatoblastoma: A success report using a combination therapy with preoperative arterial embolization. ( 28473171 )
2017
12
The Collagen Gel Droplet-embedded Culture Drug Sensitivity Test in Relapsed Hepatoblastoma. ( 28562516 )
2017
13
A Challenging Case of Hepatoblastoma Concomitant with Autosomal Recessive Polycystic Kidney Disease and Caroli Syndrome-Review of the Literature. ( 28638817 )
2017
14
Surgical treatment of childhood hepatoblastoma in the Netherlands (1990-2013). ( 27730288 )
2017
15
Downregulation of transcription factor GATA4 sensitizes human hepatoblastoma cells to doxorubicin-induced apoptosis. ( 28349834 )
2017
16
A systematic surgical approach to hepatoblastoma with intracardiac extension. ( 28457172 )
2017
17
Ante situm liver resection with inferior vena cava replacement under hypothermic cardiopolmunary bypass for hepatoblastoma: Report of a case and review of the literature. ( 28651228 )
2017
18
Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma. ( 28674120 )
2017
19
Multidisciplinary management of hepatoblastoma in children: Experience from a developing country. ( 27781375 )
2017
20
Complete remission of refractory hepatoblastoma after liver transplantation in a child with sorafenib monotherapy: A new hope? ( 28696063 )
2017
21
Recurrent Scapular Metastasis From Hepatoblastoma Shown on FDG PET/CT and F-DOPA PET/CT. ( 28806258 )
2017
22
Multimodality Treatment Outcome of Hepatoblastoma in a Resource Limited Country. ( 28588161 )
2017
23
Prognostic roles of pathology markers immunoexpression and clinical parameters in Hepatoblastoma. ( 28851352 )
2017
24
Fatal Central Nervous System Post-Transplant Lymphoproliferative Disease in a Patient Who Underwent Liver Transplantation for Hepatoblastoma. ( 28837514 )
2017
25
Hepatoblastoma in children aged less than six months at diagnosis: A report from the SIOPEL group. ( 28921839 )
2017
26
Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. ( 27775819 )
2017
27
Hepatoblastoma: Transplant Versus Resection Experience in a Latin American Transplant Center. ( 28620649 )
2017
28
Exosomal miR-34s panel as potential novel diagnostic and prognostic biomarker in patients with hepatoblastoma. ( 28277300 )
2017
29
Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. ( 27884679 )
2017
30
Hepatoblastoma and Wolf-Hirschhorn syndrome: Coincidence or a new feature of a rare disease? ( 28786167 )
2017
31
Genetic Counselor Practices Involving Pediatric Patients with FAP: an Investigation of their Self-Reported Strategies for Genetic Testing and Hepatoblastoma Screening. ( 27913912 )
2016
32
Genome-wide analysis of DNA methylation in hepatoblastoma tissues. ( 27446465 )
2016
33
GATA4 promotes hepatoblastoma cell proliferation by altering expression of miR125b and DKK3. ( 27788486 )
2016
34
Enhancer of zeste homolog 2 depletion arrests the proliferation of hepatoblastoma cells. ( 26848027 )
2016
35
Coordinated Activities of Multiple Myc-dependent and Myc-independent Biosynthetic Pathways in Hepatoblastoma. ( 27738108 )
2016
36
Pancreatoblastoma masquerading as hepatoblastoma: A diagnostic dilemma. ( 27046982 )
2016
37
Hepatoblastoma in a mosaic trisomy 18 child with hemihypertrophy. ( 26795740 )
2016
38
Regulatory network analysis of genes and microRNAs in human hepatoblastoma. ( 27895778 )
2016
39
Benefit of early inflow exclusion during living donor liver transplantation for unresectable hepatoblastoma. ( 27325360 )
2016
40
Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma. ( 27635950 )
2016
41
Hepatitis B virus X protein mediated suppression of miRNA-122 expression enhances hepatoblastoma cell proliferation through cyclin G1-p53 axis. ( 27528885 )
2016
42
Therapeutic Innovations for Targeting Hepatoblastoma. ( 27793881 )
2016
43
11C-Acetate Positron Emission Tomography for Detection of Occult Metastatic Recurrence in Hepatoblastoma. ( 26907645 )
2016
44
Hepatoblastoma and Abernethy Malformation Type I: Case Report. ( 27467369 )
2016
45
Diagnostic and prognostic values of serum exosomal microRNA-21 in children with hepatoblastoma: a Chinese population-based study. ( 27601233 )
2016
46
Corrigendum: First Experience of Ultrasound-guided Percutaneous Ablation for Recurrent Hepatoblastoma after Liver Resection in Children. ( 27632926 )
2016
47
Hepatoblastoma in Explanted Livers of Patients With Biliary Atresia. ( 27457778 )
2016
48
Targeting long non-coding RNA-TUG1 inhibits tumor growth and angiogenesis in hepatoblastoma. ( 27362796 )
2016
49
Multidisciplinary effort in treating children with hepatoblastoma in China. ( 26945966 )
2016
50
Truncated neurokinin-1 receptor is an ubiquitous antitumor target in hepatoblastoma, and its expression is independent of tumor biology and stage. ( 26870298 )
2016

Variations for Hepatoblastoma

ClinVar genetic disease variations for Hepatoblastoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 APC NM_000038.5(APC): c.4183A> T (p.Ser1395Cys) single nucleotide variant Pathogenic rs137854578 GRCh37 Chromosome 5, 112175474: 112175474
2 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
3 CTNNB1 NM_001904.3(CTNNB1): c.94G> T (p.Asp32Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs28931588 GRCh37 Chromosome 3, 41266097: 41266097

Copy number variations for Hepatoblastoma from CNVD:

7
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 48501 11 1 52900000 Methylation H19 Hepatoblastoma
2 48504 11 1 52900000 Methylation IGF2 Hepatoblastoma

Expression for Hepatoblastoma

Search GEO for disease gene expression data for Hepatoblastoma.

Pathways for Hepatoblastoma

Pathways related to Hepatoblastoma according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.57 APC BCL2L1 CASP3 CTNNB1 HGF MET
2 12.56 APC BCL2L1 CASP3 CTNNB1 HGF MET
3
Show member pathways
12.39 APC BCL2L1 BIRC5 CASP3 CTNNB1 HGF
4
Show member pathways
12.32 BCL2L1 CASP3 CTNNB1 MET
5 12.3 APC BIRC5 CTNNB1 HNF1A
6 12.3 APC BCL2L1 BIRC5 CASP3 CTNNB1 HGF
7
Show member pathways
12.25 BCL2L1 BIRC5 IGF2 MET
8 12.01 AFP APC BIRC5 CTNNB1
9 11.94 APC BCL2L1 BIRC5 CASP3 CTNNB1
10 11.93 APC BCL2L1 CASP3 CTNNB1
11 11.85 AFP APC HGF MET
12 11.74 CASP3 CTNNB1 GPC3 HGF IGF2 MET
13
Show member pathways
11.73 CTNNB1 HGF MET
14
Show member pathways
11.68 BCL2L1 BIRC5 CASP3
15 11.6 BCL2L1 BIRC5 CASP3
16 11.38 APC CTNNB1 HNF1A
17 11.33 AFP APOA1 HNF1A
18 11.27 BCL2L1 BIRC5 CASP3 HNF1A
19 11.23 CTNNB1 HGF MET
20 10.91 ABCB1 BCL2L1 CASP3
21 10.66 ABCB1 BCL2L1
22 10.4 APC CTNNB1 HGF MET

GO Terms for Hepatoblastoma

Cellular components related to Hepatoblastoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 beta-catenin destruction complex GO:0030877 9.16 APC CTNNB1
2 catenin complex GO:0016342 8.96 APC CTNNB1
3 Wnt signalosome GO:1990909 8.62 APC CTNNB1

Biological processes related to Hepatoblastoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.8 BCL2L1 BIRC5 CTNNB1 HGF IGF2
2 negative regulation of inflammatory response GO:0050728 9.54 APOA1 HGF PPARA
3 cellular protein metabolic process GO:0044267 9.46 AFP APOA1 GPC3 IGF2
4 fatty acid transport GO:0015908 9.43 HNF1A PPARA
5 hepatocyte growth factor receptor signaling pathway GO:0048012 9.32 HGF MET
6 entry of bacterium into host cell GO:0035635 9.26 CTNNB1 MET
7 embryonic placenta morphogenesis GO:0060669 8.65 CDKN1C
8 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 8.62 HGF MET

Molecular functions related to Hepatoblastoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein serine/threonine kinase inhibitor activity GO:0004861 8.62 CASP3 CDKN1C

Sources for Hepatoblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....